ENDO SHUNJI

Dr. ENDO SHUNJI

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
SYSachiko Yamamoto
Sachiko Yamamoto
HKHisato Kawakami
Hisato Kawakami
TKTakayuki Kii
Takayuki Kii
HHhiroki hara
hiroki hara
RKRyohei Kawabata
Ryohei Kawabata
TSTaroh Satoh
Taroh Satoh

7 January 2022 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
ESENDO SHUNJI
ENDO SHUNJI
TYTomoki Yamatsuji
Tomoki Yamatsuji
YFYoshinori Fujiwara
Yoshinori Fujiwara
MHMasaharu Higashida
Masaharu Higashida
HKHisako Kubota
Hisako Kubota
TUTomio Ueno
Tomio Ueno
Background: Patients with gastric cancer are aging in Japan. It is not clear which patients and which surgical procedures have survival benefits after gastrectomy. A multivariate analysis was performed. Methods: The medical records of 166 patients aged ≥ 80 years who underwent gastrectomy without macroscopic residual tumors were retrospectively reviewed. Univariate and multivariate analyses using Cox proportional hazard models were performed to detect prognostic factors for overall survival. Results: In univariate analyses, age (≥ 90 vs. ≥ 80, < 85), performance status (3 vs. 0), American Society of Anesthesiologists physical status (ASA-PS) (3, 4 vs. 1, 2), Onodera’s prognostic nutritional index (< 40 vs. ≥ 45), the physiological score of the Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) (≥ 40 vs. ≥ 20, ≤ 29), surgical approach (laparoscopic vs. open), extent of gastrectomy (total, proximal vs. distal), extent of lymphadenectomy (D1 vs. ≥ D2), pathological stage (II–IV vs. I), and residual tumor (R1 vs. R0) were significantly correlated with worse overall survival. Multivariate analysis revealed that ASA-PS [3, 4 vs. 1, 2, hazard ratio (HR) 2.30, 95% confidence interval (CI) 1.24–4.24], extent of gastrectomy (total vs. distal, HR 2.17, 95% CI 1.10–4.31) (proximal vs. distal, HR 4.05, 95% CI 1.45–11.3), extent of lymphadenectomy (D0 vs. ≥ D2, HR 12.4, 95% CI 1.58–97.7), and pathological stage were independent risk factors for mortality. Conclusions: ASA-PS was a useful predictor for postoperative mortality. Gastrectomy including cardia is best avoided.

23 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ESENDO SHUNJI
ENDO SHUNJI
TTTetsuji Terazawa
Tetsuji Terazawa
MGMasahiro Goto
Masahiro Goto
RTRyo Tanaka
Ryo Tanaka
TKTakeshi Kato
Takeshi Kato
TSTaroh Satoh
Taroh Satoh
Background: Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to confirm the superiority of neoadjuvant S-1 plus cisplatin followed by D2 gastrectomy over upfront surgery, showed no survival benefit for neoadjuvant S-1 plus cisplatin. In Korea, the PRODIGY study, which was a phase III study of neoadjuvant docetaxel plus oxaliplatin plus S-1 (DOS) followed by surgery and adjuvant S-1 versus surgery and adjuvant S-1 for gastric cancer of T2-3N+ or T4Nany, showed that progression-free survival (PFS) was significantly superior in the neoadjuvant DOS arm. Therefore, DOS therapy may be a promising candidate for preoperative chemotherapy for large type 3 or type 4 gastric cancer. Methods: Preoperative docetaxel 40 mg/m2 and oxaliplatin 100 mg/m2 will be intravenously administered on day1 every three weeks. S-1 will be orally administered 80 mg/m2 on days 1–14 of a 21-day cycle. Patients will receive three courses of treatment and gastrectomy with ≥D2 lymph node dissection. Postoperative S-1 plus docetaxel therapy (DS) will be administered according to the JACCRO GC-07 (START-2) study. The primary endpoint is the 3-year PFS rate. Secondary endpoints include PFS time, overall survival time, pathological response rate, response rate according to RECIST version1.1, proportion of completion of neoadjuvant chemotherapy, R0 resection rate, proportion of completion of surgery, proportion of completion of protocol treatment, proportion of negative conversion of CY, adverse event occurrence rate, and nutritional evaluation. The null hypothesis for the 3-year PFS rate is 45% and the expected value is 60%. The total sample size is 46 considering that the registration period and follow-up period are two and three years, respectively. Discussion: This is a prospective, multicenter, single-arm, open-label, phase II trial assessing the efficacy and safety of preoperative DOS and postoperative DS for large type 3 or type 4 gastric cancer. The results will inform future phase III trials and are expected to lead to new treatment strategies for large type 3 or type 4 gastric cancer. Trial registration: Registered with Japan Registry of Clinical Trials on October 11, 2019 (jRCTs051190060).

17 February 2021 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ESENDO SHUNJI
ENDO SHUNJI
KNKazuhiro Nishikawa
Kazuhiro Nishikawa
MIMasakazu Ikenaga
Masakazu Ikenaga
KFKazumasa Fujitani
Kazumasa Fujitani
JKJunji Kawada
Junji Kawada
TUTomio Ueno
Tomio Ueno

20 May 2021 in Surgery Today
Verified
Journal Article
Closed access
PDF file
ESENDO SHUNJI
ENDO SHUNJI
YFYoshinori Fujiwara
Yoshinori Fujiwara
MHMasaharu Higashida
Masaharu Higashida
HKHisako Kubota
Hisako Kubota
HMHideo Matsumoto
Hideo Matsumoto
TUTomio Ueno
Tomio Ueno

23 November 2022 in Surgery Today
Verified
Journal Article
Closed access
PDF file
ESENDO SHUNJI
ENDO SHUNJI
TYTomoki Yamatsuji
Tomoki Yamatsuji
YFYoshinori Fujiwara
Yoshinori Fujiwara
MHMasaharu Higashida
Masaharu Higashida
HKHisako Kubota
Hisako Kubota
TUTomio Ueno
Tomio Ueno